Profile:
LCZ696, also known by its brand name Entresto, represents a novel class of medication primarily used in the treatment of heart failure. It is a combination drug that includes two active ingredients: sacubitril and valsartan. Sacubitril is a neprilysin inhibitor, while valsartan is an angiotensin receptor blocker (ARB). This unique composition allows LCZ696 to offer a dual mechanism of action aimed at improving cardiac function and reducing the risk associated with heart failure.
How LCZ696 Works:
Sacubitril works by inhibiting neprilysin, an enzyme responsible for breaking down natriuretic peptides. These peptides play crucial roles in reducing blood pressure and enhancing sodium excretion. By preventing their breakdown, sacubitril helps to lower blood pressure and reduce fluid overload.
Valsartan, on the other hand, blocks the action of angiotensin II on its receptors. Angiotensin II is a powerful vasoconstrictor that raises blood pressure and promotes sodium retention. By blocking this effect, valsartan contributes to lowering blood pressure and decreasing workload on the heart.
Indications:
LCZ696 is indicated for treating chronic heart failure in adults with reduced ejection fraction (HFrEF), aiming to decrease hospitalization rates for heart failure patients and reduce cardiovascular death risks.
Benefits:
Clinical trials have demonstrated that LCZ696 significantly reduces mortality from cardiovascular causes when compared to enalapril alone (a standard treatment for heart failure). Patients taking LCZ696 have also shown improvements in symptoms related to heart failure such as reduced shortness of breath and fatigue.
Usage:
It's important for patients prescribed LCZ696 to follow their healthcare provider's instructions closely regarding dosage due to potential side effects like hypotension (low blood pressure), hyperkalemia (high potassium levels), or renal impairment.
Considerations:
Before starting LCZ696, patients should inform their healthcare providers about any existing medical conditions such as kidney problems or if they are pregnant or plan to become pregnant due it potential fetal harm
In summary, LCZ696 offers hope new approach managing chronic HF through its innovative combination targeting different aspects disease pathology However careful monitoring patient education essential ensure safe effective use this medication
China
